ALK has obtained European approval for its HDM-SLIT (house dust mite sublingual allergy immunotherapy tablet) against allergic rhinitis and allergic...
Merck announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite...
Altamira Therapeutics Ltd. announced the publication of the detailed results from its clinical trial with Bentrio nasal spray in house dust mite (“HDM”) allergic rhinitis
ACARIZAX is indicated in adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions: • persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication • house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment (see section 4.3). ACARIZAX is indicated in adolescents (12-17 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.
ALK has presented trial results on Mitizax (sublingual allergy immunotherapy tablet or SLIT-tablet) for House Dust Mite (HDM) respiratory Allergic...
ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts.
ALK Abello announced positive top-line results from the pivotal Phase III MITRA trial conducted with the allergy immunotherapy tablet against...
ALK has announced that The Journal of the American Medical Association (JAMA) has published results from a Phase III clinical...